Jake Miller, MD, on Peyronie disease research from SMSNA 2024

In this video, Jake Miller, MD, gives an overview of the study “Satisfaction After Collagenase Clostridium Histolyticum May Be Impacted by the Accuracy of Patient-Predicted Penile Curvature,” which he presented at the 2024 Sexual Medicine Society of North America Fall Scientific Meeting in Scottsdale, Arizona. Miller is a senior urology resident at the University of California, Irvine.

Transcription:

Please provide an overview of this study and its notable findings.

The trials that we've been doing for the Peyronie projects is a large multi-center database that we've created. It's the first large cohort series that is not industry funded as well, that we independently put together. As of now for SMSNA, we collected data from 4 different sites, so that was from UC Irvine, from University of Chicago, University of Miami, and then also Baylor as well. And then since then, we've added 2 additional sites, UCSD and then Indiana as well, and so we should have that data shortly as well. For SMSNA, we focused mainly on 4 different topics for our projects, so the impact of patient-reported curvature vs a urologist's measure of penile curvature, to see if that impacts how patients are perceiving their treatment over time, looking at the impacts of testosterone, which was a previously debated area in the field, as well. And then some other things, looking at more complex curvatures as well, and so looking at some of the curvatures that weren't necessarily included in the initial data that was used for the FDA approval.

For the patient-predicted curvature, which was the one that our team specifically ended up presenting, we found actually that patients who underpredict their curve during the initial visit, prior to having a formal measurement of their penile curvature, actually ended up having a higher satisfaction following treatment, which is interesting. We did not necessarily find that those who are overpredicting their curvature had a worse treatment, but we think in part that might be something relating to the data. Potentially, the people who are overpredicting their curvature actually have a sense to almost catastrophize their results to the point where even a large reduction in curvature might not reach their satisfaction, and as we know that there's a limited range of improvement with that medication that we're using, it can potentially be useful to look at those discrepancies prior to treatment and then to have an honest conversation with those patients about the expectations for the treatment and realizing if the patient is unlikely to achieve a satisfactory effect with what you're expecting, possibly to discuss other treatments.

This transcript was AI generated and edited by human editors for clarity.